Developing new antibodies to target a specific protein in cancer cells
Novel biologic therapeutics targeting vacuolar ATPase localized on plasma membrane
This study is working on creating special antibodies that can target a specific protein linked to aggressive cancers caused by the KRAS gene, with the goal of making cancer treatments safer and more effective for patients by reducing side effects on healthy cells.
Quick facts
| Grant type | R21 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | New York University School of Medicine NIH-funded |
| Lab location | 1 site (New York, United States) |
| Project ID | NIH-11112635 on NIH RePORTER |
What this research studies
This research aims to create novel antibodies that specifically target the plasma membrane vacuolar ATPase (pmVATPase), a protein linked to certain aggressive cancers driven by the KRAS gene. By focusing on pmVATPase, the project seeks to improve the selectivity of cancer treatments, reducing toxicity associated with current therapies that affect normal cell functions. The approach involves understanding the 3D structure of pmVATPase to design effective antibodies that can minimize harm to healthy cells while attacking cancer cells. This innovative method could lead to more effective anti-cancer therapies.
Who could benefit from this research
Good fit: Ideal candidates for this research are patients with KRAS-driven cancers that are difficult to treat with existing therapies.
Not a fit: Patients with cancers not driven by KRAS or those who do not express pmVATPase may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to more targeted and less toxic cancer treatments for patients.
How similar studies have performed: Other research has shown promise in targeting specific proteins in cancer therapy, but this approach focusing on pmVATPase is relatively novel.
Where this research is happening
New York, United States
- New York University School of Medicine — New York, United States (Active)
Researchers
- Principal investigator: Koide, Shohei — New York University School of Medicine
- Study coordinator: Koide, Shohei
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.